EUVIMEDEUVIMED entdecken
Open Access

Role of GLP‐1 Receptor Agonists in Managing Cancer Therapy–Related Cardiac Dysfunction

Aravinthan Vignarajah iD, San Kim iD, Moath Albliwi iD, Hyunjun Max Ahn, Aleksandar Izda iD, Faris Naffa, Nishanthi Vigneswaramoorthy, Shimoli Barot iD, Gautam Shah iD

Journal of the American Heart Association · 18.11.2025 · 14 (22)

DOI: 10.1161/jaha.125.040919 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Heart Association, erschienen am 18.11.2025. Verfasst von Aravinthan Vignarajah und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine Cleveland Clinic Fairview Hospital Cleveland OH USA. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Neoplasms, Antineoplastic Agents, Heart Failure. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Current anticancer treatments can result in cancer therapy–related cardiac dysfunction (CTRCD). While glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have demonstrated cardioprotective properties, their role in CTRCD has not been previously explored.

Methods

This retrospective cohort study utilized the TriNetX research network. Adults aged ≥18 years who had a cancer history and who underwent antineoplastic therapy and developed CTRCD between January 1, 2012 and January 1, 2023 were included. Among patients on guideline‐directed medical therapy for heart failure, 2 groups were identified: GLP‐1 RA users and nonusers. Propensity score matching (1:1) was conducted based on demographics, comorbid conditions, and concurrent medications, yielding a matched sample of 837 patients. Outcomes were assessed over a 1‐year follow‐up period.

Results

The study cohort found 4982 patients with CTRCD; 837 received GLP‐1 RA therapy (mean age: 69.0 years; 43.8% female; 70.4% White). Compared with nonusers, those treated with GLP‐1 RAs alongside guideline‐directed medical therapy had significantly lower rates of all‐cause mortality (hazard ratio, 0.57 [95% CI, 0.43–0.77]; P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide-1 Receptor AgonistsNeoplasmsAntineoplastic AgentsHeart FailureIncretinsHumansFemaleMaleAgedRetrospective StudiesMiddle AgedCardiotoxicityTreatment Outcome

Stichwörter der Autor:innen

cancercancer therapy‐related cardiac dysfunctionglucagon‐like peptide‐1 receptor agonistsheart failure

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsAntineoplastic AgentsIncretins

Autor:innen und Institutionen

  • Department of Medicine Cleveland Clinic Fairview Hospital Cleveland OH USA.
  • Cleveland Clinic Lerner College of Medicine Cleveland OH USA.
  • Department of Internal Medicine Ascension Health, Saint Agnes Baltimore MD USA.
  • Department of Medicine SUNY Upstate Medical University Hospital Syracuse NY USA.
  • Taussig Cancer Institute Cleveland Clinic Foundation Cleveland OH USA.
  • Heart, Vascular & Thoracic Institute Cleveland Clinic Foundation/Fairview Hospital Cleveland OH USA.

ORCID-Profile: Aravinthan Vignarajah, San Kim, Moath Albliwi, Aleksandar Izda, Shimoli Barot, Gautam Shah

Zitieren

APA

Vignarajah, A., Kim, S., Albliwi, M., Ahn, H. M., Izda, A., Naffa, F., Vigneswaramoorthy, N., Barot, S., & Shah, G. (2025). Role of GLP‐1 Receptor Agonists in Managing Cancer Therapy–Related Cardiac Dysfunction. Journal of the American Heart Association, 14(22). https://doi.org/10.1161/jaha.125.040919

Vancouver

Vignarajah A, Kim S, Albliwi M, Ahn HM, Izda A, Naffa F, et al. Role of GLP‐1 Receptor Agonists in Managing Cancer Therapy–Related Cardiac Dysfunction. Journal of the American Heart Association. 2025;14(22). doi:10.1161/jaha.125.040919

BibTeX
@article{Vignarajah2025,
  author = {Vignarajah, Aravinthan and Kim, San and Albliwi, Moath and Ahn, Hyunjun Max and Izda, Aleksandar and Naffa, Faris and Vigneswaramoorthy, Nishanthi and Barot, Shimoli and Shah, Gautam},
  title = {Role of GLP‐1 Receptor Agonists in Managing Cancer Therapy–Related Cardiac Dysfunction},
  journal = {Journal of the American Heart Association},
  year = {2025},
  volume = {14},
  number = {22},
  doi = {10.1161/jaha.125.040919}
}
Kostenlos starten →